| 摘要: |
| 目的 研究超声引导下热消融对晚期结肠癌(COAD)伴肝转移患者预后的影响。方法 选取2018年6月-2021年6月在本院就诊的102例晚期COAD伴肝转移患者,按随机数字表法分为2组,观察组和对照组各51例。对照组贝伐珠单抗联合常规化疗治疗,观察组在对照组基础上采用超声引导下微波热消融术(MWA)治疗；比较两组患者疗效、免疫功能、预后。结果 治疗后,观察组客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(P<0.05)；2组治疗后CD3+、CD4+、CD8+水平均有不同程度下降,但观察组CD3+、CD4+、CD4+/CD8+水平均高于对照组,CD8+低于对照组(P＜0.05)；治疗后,2组胃肠道反应、食欲减退、疲劳乏力等不良反应比较差异无统计学意义(P＞0.05)；观察累积无复发生存率73.40%,显著高于对照组(χ2=4.581、P=0.032),但观察组与对照组的总生存率比较差异无统计学意义(χ2=1.330、P=0.249)。结论 超声引导下热消融联合贝伐珠单抗治疗晚期COAD伴肝转移患者能够有效提升治疗效果,缓解患者免疫功能抑制,改善累积无复发生存率,且安全可靠。 |
| 关键词: 结肠癌 晚期 超声 肝转移 贝伐珠单抗 热消融 免疫 |
| DOI： |
| 投稿时间：2023-05-25修订日期：2023-09-08 |
| 基金项目: |
|
| Effects of ultrasound-guided thermal ablation on prognosis in patients with advanced colon adenocarcinoma and colorectal liver metastasis |
| hanxiaojun,yuanli,guodaoning |
| () |
| Abstract: |
| Objective To explore the effects of ultrasound-guided thermal ablation on prognosis in patients with advanced colon adenocarcinoma (COAD) and colorectal liver metastasis (CLMs). Methods A total of 102 patients with advanced COAD and CLMs treated in the hospital were enrolled between June 2018 and June 2021. According to random number table method, they were divided into observation group and control group, 51 cases in each group. The control group was treated with bevacizumab and routine chemotherapy, while observation group was additionally treated with microwave thermal ablation (MWA). The curative effect, immune function and prognosis in the two groups were compared. Results After treatment, objective remission rate (ORR) and disease control rate (DCR) in observation group were higher than those in control group (P<0.05). After treatment, levels of CD3+, CD4+ and CD8+ were decreased in both groups. The levels of CD3+, CD4+ and CD4+/CD8+ in observation group were higher than those in control group, while CD8+ was lower than that in control group (P<0.05). After treatment, there was no significant difference in adverse reactions (gastrointestinal reactions, loss of appetite, fatigue) between the two groups (P>0.05). The cumulative recurrence-free survival rate in observation group was 73.40%, significantly higher than that in control group (χ2=4.581, P=0.032). There was no significant difference in the overall survival rate between observation group and control group (χ2=1.330, P=0.249). Conclusion Ultrasound-guided thermal ablation combined with bevacizumab can effectively improve curative effect, relieve immune suppression and improve cumulative recurrence-free survival rate in patients with advanced COAD and CLMs. |
| Key words: Colon adenocarcinoma Advanced Ultrasound Colorectal liver metastasis Bevacizumab Thermal ablation Immunity |
